JournalArta
Monday, November 23, 2026 · JakartaS&P 6,910.39 ▼3.70%USD/IDR 18,158 ▼0.42%
JournalArta
Global Edition
beyond headlines
Advertisement

Bristol Myers Squibb Trails Novo Nordisk on Profit Margin

Bristol Myers Squibb and Novo Nordisk posted similar revenue in the 12 months through September 2026, but Novo reported a substantially higher net margin. The drugmakers face different pressures, including US drug-price negotiations, patent expirations and competition in obesity treatments.

By matthew jonathan
WIB2 min read
Bristol Myers Squibb Trails Novo Nordisk on Profit Margin
Bristol Myers Squibb Trails Novo Nordisk on Profit Margin

Bristol Myers Squibb reported a lower profit margin than Novo Nordisk despite similar revenue in the 12 months ended September 30, 2026. The figures show contrasting earnings profiles as both drugmakers face pricing and competitive pressures.

Bristol Myers recorded approximately $50.0 billion in revenue, up roughly 4.2% from the previous year. Net income was approximately $9.2 billion, with a net margin of roughly 18.5%.

Novo reported about $49.0 billion in revenue, an increase of approximately 5.7%. Its net income was around $16.6 billion, and its net margin was roughly 33.9%.

Bristol Myers develops treatments for cancer, blood disorders and neurological conditions. Its collaborations include Johnson & Johnson, Zai Lab and Merck & Co.

Advertisement

Most of its sales go through wholesalers and distributors. Its three largest US wholesalers account for a substantial portion of global gross revenue, leaving the company exposed to those customer relationships.

Novo focuses on chronic diseases, particularly obesity and diabetes. It also operates in rare blood and endocrine disorders across the United States, Europe and China. Demand for Ozempic and Wegovy supports its profitability.

The companies also differ in their balance sheets. As of December 2025, Bristol Myers had a debt-to-equity ratio of nearly 2.6 times, compared with roughly 0.7 times for Novo.

That ratio compares debt with shareholder equity. Their current ratios, which compare short-term assets with short-term liabilities, were roughly 1.3 times for Bristol Myers and nearly 0.8 times for Novo.

Advertisement

For the fiscal year ended December 31, 2025, Bristol Myers reported approximately $12.8 billion in free cash flow. Novo reported approximately $4.3 billion.

Bristol Myers faces pricing pressure and reimbursement restrictions under the US Inflation Reduction Act. The law has led to government-set prices for Eliquis and Pomalyst, while upcoming negotiations for Orencia could pressure revenue.

The company also faces the loss of market exclusivity for Eliquis, Opdivo and Revlimid. Generic competition could reduce revenue from those products.

Novo faces competition in obesity treatments from Eli Lilly & Co. and Pfizer. It must also contend with US pricing pressure and demand for manufacturing capacity for Wegovy and Ozempic.

Advertisement

Analysts expect Novo's sales to decline about 3% in fiscal 2026 and net income to fall 4%. They expect growth to resume as new products come online.

Bristol Myers' current fiscal-year revenue is expected to rise 3% to $49.8 billion. Net income is expected to rise more than 40% to $11.2 billion.

Bristol-Myers SquibbNovo Nordisk
Advertisement
What Kind of Holiday Spender Are You? Take the Black Friday QuizTake the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
Advertisement
Most Read
  1. 1GTA 6 Draws Review Bombing on MetacriticGTA 6 Draws Review Bombing on Metacritic
  2. 2Dow Jones Futures Await Reopening After Tech Stocks SlideDow Jones Futures Await Reopening After Tech Stocks Slide
  3. 3Jensen Huang Denies Abuse Claims After Nvidia ExitJensen Huang Denies Abuse Claims After Nvidia Exit
  4. 4Micron Says Memory Has Changed as Shares Fall 13.89%Micron Says Memory Has Changed as Shares Fall 13.89%
  5. 5Brielle Biermann Marries Billy Seidl in Naples, FloridaBrielle Biermann Marries Billy Seidl in Naples, Florida
Advertisement
Don't Miss

Latest News

All stories →
  1. US Army Plans Iowa Blast Despite Court-Ordered PauseWorld · United StatesUS Army Plans Iowa Blast Despite Court-Ordered PauseNov 23
  2. Australia’s power prices would be up to 50% higher, economist saysBusiness · EnergyAustralia’s power prices would be up to 50% higher, economist saysNov 23
  3. Japan Defeats USA 7-5 to Win Softball All-Star SeriesSport · More SportsJapan Defeats USA 7-5 to Win Softball All-Star SeriesNov 23
  4. Liverpool Spoil Mauricio Pochettino’s Debut With 4-0 WinSport · FootballLiverpool Spoil Mauricio Pochettino’s Debut With 4-0 WinNov 23
  5. Advertisement
  6. Wests Tigers Allow Fainu Loan as Fogarty Talks ContinueSport · More SportsWests Tigers Allow Fainu Loan as Fogarty Talks ContinueNov 23
  7. Endometriosis Study Identifies 27 New Genetic CluesLifestyle · Food & HealthEndometriosis Study Identifies 27 New Genetic CluesNov 23
  8. Labor Risks Losing Heartland Seats in Victoria, Poll FindsWorld · AustraliaLabor Risks Losing Heartland Seats in Victoria, Poll FindsNov 23
  9. Stuffy Nose Remedies Fail When Patients Rely on AntibioticsLifestyleStuffy Nose Remedies Fail When Patients Rely on AntibioticsNov 23